|
| 34643650 | Effect of Costimulatory Blockade With Abatacept After Ustekinumab Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: The PAUSE Randomized Clinical Trial. | JAMA Dermatol | 2021 |
| 34236691 | The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score. | Dermatology and Therapy | 2021 |
| 33858978 | Psoriasis Characteristics for the Early Detection of Psoriatic Arthritis. | Journal of Rheumatology | 2021 |
| 33512665 | Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities. | Dermatology and Therapy | 2021 |
| 31705649 | Defining drug-free remission of skin disease in patients with plaque psoriasis. | British Journal of Dermatology | 2020 |
| 30317662 | Systemic corticosteroid use in psoriasis: a national survey of board-certified dermatologists. | Journal of the European Academy of Dermatology and Venereology | 2019 |
| 31603636 | Non-Melanoma Skin Cancer Risk Among Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR) | Journal of Drugs in Dermatology | 2019 |
| 29747219 | Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). | British Journal of Dermatology | 2018 |
| 30301895 | Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients. | Nat Commun | 2018 |
| 30324088 | The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA. | Psoriasis: Targets and Therapy | 2018 |
| 27908543 | From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. | Journal of the American Academy of Dermatology | 2017 |
| 28537254 | Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants. | Nat Commun | 2017 |
| 28973304 | Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling. | Hum Mol Genet | 2017 |
| 26247843 | Desired Improvement Tool (DIT): A tool to assess desire for improvement in psoriasis patients. | | 2016 |
| 25779603 | Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study. | Arthritis Care Res (Hoboken) | 2016 |
| 27027388 | Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). | Journal of the European Academy of Dermatology and Venereology | 2016 |
| 26802234 | microRNAs in Psoriasis. | | 2016 |
| 25182136 | Fine mapping of eight psoriasis susceptibility loci. | Eur J Hum Genet | 2015 |
| 25582533 | WITHDRAWN: Experience with ustekinumab in patients with psoriasis enrolled in a large, multicenter, prospective, disease-based registry (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). | Journal of the American Academy of Dermatology | 2015 |
| 25693783 | Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis. | Journal of the European Academy of Dermatology and Venereology | 2015 |
| 25903422 | Genome-wide meta-analysis identifies multiple novel associations and ethnic heterogeneity of psoriasis susceptibility. | Nat Commun | 2015 |
| 25307931 | Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. | British Journal of Dermatology | 2015 |
| 25968164 | Impact of pigmentary disorders on quality of life in Japan: Interest of the BeautyQoL instrument. | Journal of Cosmetic and Laser Therapy | 2015 |
| 25939698 | Enhanced meta-analysis and replication studies identify five new psoriasis susceptibility loci. | Nat Commun | 2015 |
| 25557081 | Onset of psoriatic arthritis during ustekinumab treatment for psoriasis: a case series of seven patients. | British Journal of Dermatology | 2015 |
| 26267724 | Essential Truths for the Care and Management of Moderate-to-Severe Psoriasis. | Journal of Drugs in Dermatology | 2015 |
| 26133392 | Quality of life assessment in cosmetics: specificity and interest of the international BeautyQol instrument. | Journal of Cosmetic Dermatology | 2015 |
| 26626624 | Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture. | Am J Hum Genet | 2015 |
| 26151787 | Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). | Journal of Drugs in Dermatology | 2015 |
| 24928705 | Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting. | Journal of the American Academy of Dermatology | 2014 |
| 25607786 | Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies. | Journal of Drugs in Dermatology | 2014 |
| 25260564 | Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical setting. | J Am Acad Dermatol | 2014 |
| 24266754 | Diagnosing and treating psoriatic arthritis: an update. | British Journal of Dermatology | 2014 |
| 24266717 | Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice. | British Journal of Dermatology | 2014 |
| 24488420 | Development of a disease activity and responder index for psoriatic arthritis--report of the Psoriatic Arthritis Module at OMERACT 11. | J Rheumatol | 2014 |
| 25028377 | Work productivity loss and fatigue in psoriatic arthritis. | Journal of Rheumatology | 2014 |
| 24894455 | Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis. | Journal of the American Academy of Dermatology | 2014 |
| 24748630 | Clinical efficacy, radiographic and safety findings through 5â¿¿years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). | Ann Rheum Dis | 2014 |
| 25087609 | Fine mapping major histocompatibility complex associations in psoriasis and its clinical subtypes. | Am J Hum Genet | 2014 |
| 23715064 | Using Hawthorne effects to improve adherence in clinical practice: lessons from clinical trials--reply. | JAMA Dermatology | 2013 |
| 22846688 | Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. | Journal of the American Academy of Dermatology | 2013 |
| 22910105 | Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis. | Journal of the American Academy of Dermatology | 2013 |
| 22975755 | Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab. | Ann Rheum Dis | 2013 |
| 23752654 | Psoriasis and the obesity epidemic: the effect of weight loss. | JAMA Dermatology | 2013 |
| 24054760 | Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort. | Journal of the American Academy of Dermatology | 2013 |
| 23157612 | Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. | Journal of the European Academy of Dermatology and Venereology | 2013 |
| 23486423 | The Dermatology Foundation: partnerships and programs focused on the future. | | 2013 |
| 23666608 | Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial. | Arthritis Care Res (Hoboken) | 2013 |
| 23378465 | Limitations in screening instruments for psoriatic arthritis: a comparison of instruments in patients with psoriasis. | Journal of Rheumatology | 2013 |
| 23161902 | Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. | Ann Rheum Dis | 2013 |